Yakubu, JibiraJibiraYakubu0000-0001-7637-0559Tagit, OyaOyaTagitPandey, Amit V.Amit V.Pandey0000-0001-8331-59022026-01-222026-01-222026-01-18https://boris-portal.unibe.ch/handle/20.500.12422/229458Introduction Prostate cancer (PC) treatment is limited by resistance mechanisms and cumulative toxicities, necessitating novel therapeutic strategies. While curcumin and piperine exhibit potent anticancer properties, their clinical utility is severely compromised by poor bioavailability and rapid metabolism.Areas Covered This review critically analyzes the preclinical and clinical landscape of curcumin and piperine nanoformulations (CPN) for the treatment of PC. We utilized PubMed and Scopus (2000-2025) to evaluate molecular mechanisms, focusing on CYP17A1 inhibition, PI3K/Akt/mTOR signaling, and ferroptosis. The report examines the physicochemical properties of nanocarriers, including PLGA and liposomes, and addresses translational barriers such as the heterogeneity of the Enhanced Permeability and Retention (EPR) effect, stromal density, and risks associated with piperine-mediated drug - drug interactions.Expert Opinion While nano-encapsulation enhances the therapeutic index of curcumin, clinical translation remains stalled by a reliance on passive targeting and insufficient manufacturing scalability. Future success depends on shifting from 'beaker' synthesis to microfluidic production (Quality by Design) and adopting active targeting (e.g. PSMA-directed delivery) to penetrate the prostate stroma. Without these strategic pivots and biomarker-driven trials, CPNs risk remaining an academic curiosity rather than evolving into a viable clinical intervention.Can Turmeric and Black Pepper Treat Prostate Cancer? A Review of Nanotechnology’s Promise and ChallengesPlain Language Summary Prostate cancer is one of the most common cancers in men. While treatments exist, advanced stages often become resistant to standard therapies that block male hormones (androgens). Additionally, standard chemotherapy can have severe side effects. Scientists are seeking safer, natural alternatives to combat these resistant tumors.Plain Language Summary Curcumin (the active ingredient in turmeric) and Piperine (from black pepper) have shown powerful anti-cancer effects in laboratory tests. Curcumin can stop the tumor from making its own steroid hormones and trigger cancer cell death. Piperine helps Curcumin work better by preventing the body from breaking it down too quickly. However, there is a catch: if you simply eat these compounds, they are digested and eliminated so fast that they never reach the tumor in effective amounts.Plain Language Summary To address the absorption issue, researchers package these compounds into nanoparticles, microscopic delivery vehicles composed of safe polymers or lipids. These ’Curcumin-Piperine Nanoparticles’ (CPNs) protect the drug, facilitate its dissolution in the bloodstream, and deliver it directly to cancer cells.Plain Language Summary This review found that while CPNs work well in mice, they are struggling to succeed in human patients for three main reasons:1. The ’Wall’ around the tumor: Human prostate tumors are surrounded by a dense tissue barrier (stroma). Simple nanoparticles often cannot push through this wall to reach the cancer cells.2. Manufacturing: Making high-quality nanoparticles in a beaker is easy; making millions of identical, safe doses for humans is difficult and requires advanced technology like microfluidics.3. Safety Risks: Piperine acts as a ’bio-enhancer,’ which means it stops the liver from clearing drugs. If a patient takes CPNs alongside chemotherapy (like docetaxel), the Piperine might accidentally cause toxic levels of chemotherapy to build up in the blood.Plain Language Summary The authors conclude that ’passive“ nanoparticles are not enough. To cross the bridge to clinical reality, future medicines must be ”active,’ meaning the nanoparticles should be equipped with a GPS-like targeting system (such as PSMA ligands) to navigate through the tumor barriers. If these engineering and safety challenges are solved, CPNs could become a valuable tool for treating prostate cancer.enAnd nanoparticle formulationsCYP17A1Steroidogenesisandrogen synthesiscurcumin nanoparticlesprostate cancer600 - Technology::610 - Medicine & healtharticle10.48620/940494154808310.1080/17425247.2026.2619094